Suppr超能文献

载凝血酶的海藻酸钙微球:一种用于经导管动脉栓塞术的新型止血栓塞材料。

Thrombin-loaded alginate-calcium microspheres: A novel hemostatic embolic material for transcatheter arterial embolization.

作者信息

Rong Jing-Jing, Liang Ming, Xuan Feng-Qi, Sun Jing-Yang, Zhao Li-Jun, Zheng Hui-Zhen, Tian Xiao-Xiang, Liu Dan, Zhang Quan-Yu, Peng Cheng-Fei, Li Fei, Wang Xiao-Zeng, Han Ya-Ling, Yu Wei-Ting

机构信息

Department of Cardiology, The General Hospital of Shenyang Military Region, Shenyang 110016, China.

Laboratory of Biomedical Material Engineering, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian 116023, China.

出版信息

Int J Biol Macromol. 2017 Nov;104(Pt A):1302-1312. doi: 10.1016/j.ijbiomac.2017.03.020. Epub 2017 Jun 1.

Abstract

Transcatheter arterial embolization (TAE) is the best non-laparotomy choice for solid visceral organs rupture and bleeding nowadays. In our previous study, a new biodegradable macromolecule material thrombin-loaded alginate-calcium microsphere (TACM) was prepared and its characteristics were investigated preliminarily. In this study, we further investigated the biocompatibility of TACMs, as well as physical characteristic, application method and effect of TACMs with thrombus (embolic agent). The in vivo results attested that TACMs were non-irritating and non-genotoxic with desired biocompatibility, although brought about a slight and temporary inflammation. Application research showed that the function of thrombin was inhibited by common contrast agents, and it was impracticable to add contrast agents in TACMs with thrombus for tracing under X-rays in TAE. Then, a novel delivery method was developed. In addition, stress resistance test indicated that the TACMs with thrombus was significantly stronger than single autologous thrombus, the optimized ratio of TACMs to whole blood was 2:3 for forming mixed thrombus. Finally, large animal experiment revealed that the novel embolic agent - TACMs mixed thrombus was effective and safe in treating hemorrhage of solid abdominal viscera by TAE.

摘要

经导管动脉栓塞术(TAE)是目前实体内脏器官破裂出血的最佳非剖腹手术选择。在我们之前的研究中,制备了一种新型可生物降解的大分子材料载凝血酶海藻酸钙微球(TACM),并对其特性进行了初步研究。在本研究中,我们进一步研究了TACM的生物相容性,以及TACM与血栓(栓塞剂)的物理特性、应用方法和效果。体内结果证明,TACM无刺激性和遗传毒性,具有理想的生物相容性,尽管会引起轻微的暂时性炎症。应用研究表明,普通造影剂会抑制凝血酶的功能,在TAE中,在含血栓的TACM中添加造影剂进行X线追踪是不可行的。然后,开发了一种新的给药方法。此外,抗应激试验表明,含血栓的TACM比单一自体血栓明显更强,形成混合血栓时TACM与全血的最佳比例为2:3。最后,大型动物实验表明,新型栓塞剂——TACM混合血栓在TAE治疗腹部实体脏器出血方面有效且安全。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验